St. Jude Medical, Inc. recently announced that the acquisition of Spinal Modulation, Inc. has been completed. St. Jude Medical claims that it is now the only medical device manufacturer worldwide that offers radiofrequency ablation (RFA), spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation therapy systems for chronic pain.

Through the acquisition, the company will now own Spinal Modulation’s Axium Neurostimulator System. It’s a form of SCS therapy and works by targeting the DRG, which contains the main sensory neurons that send pain signals from the peripheral nerves to the brain.

The system leverages an implantable medical device that sends mild electrical pulses to the DRG to disrupt the pain signals on the way to the brain. It currently has CE Mark in the European Union for chronic intractable pain management and TGA approval in Australia for managing chronic and intractable pain of the trunk and limbs.

The ACCURATE study is a prospective, randomized, multi-center, controlled study that evaluated the safety and efficacy of the system and the results will be presented at the 12th annual International Neuromodulation Society Congress from June 6 to 11. A PMA application seeking marketing approval in the U.S. has been submitted to the FDA.

“We’re confident the Axium system will further support our goal of providing physicians multiple options to tailor treatment for patients with chronic pain.” Michael T. Rousseau, chief operating officer for St. Jude Medical, said in a statement.

Business Affairs Homepage